Oppenheimer Lifts Target to $150 as Merck’s $28-32B Bid Collapse Sends Shares Down 17%
Investment bank Oppenheimer retained its 'Outperform' rating on Revolution Medicines, lifting its price target from $75 to $150 after Merck walked away from $28–32 billion buyout negotiations that triggered a near 17% share decline. AbbVie’s prior advanced acquisition discussions and the company’s roughly $18.9 billion market valuation indicate sustained takeover interest.
1. Buyout Talks with Major Pharma Collapse
Revolution Medicines experienced a nearly 17% share decline following reports that Merck & Co. withdrew its buyout proposal. Negotiations, which had valued Revolution Medicines at roughly $30 billion, stalled over disagreements on the acquisition price. Merck’s disciplined approach to high-growth oncology assets—typically targeting deals below $15 billion—was cited by executives as a key factor in the decision to walk away from discussions.
2. Optimistic Analyst Reaffirmation
Despite the setback, Oppenheimer analysts maintained their outperform recommendation on Revolution Medicines and raised their price target from $75 to $150. The firm emphasized confidence in the company’s targeted therapy pipeline and noted robust investor interest in its KRAS-inhibitor programs. This bullish stance signals that institutional investors continue to view Revolution Medicines as well positioned for long-term growth.
3. Renewed Acquisition Interest from AbbVie
AbbVie reportedly engaged in advanced acquisition talks earlier in January, indicating that suitors beyond Merck remain interested. Industry insiders suggest that AbbVie’s pursuit highlighted the strategic value of Revolution Medicines’ novel oncology platforms. With a current market capitalization near $18.9 billion and an average daily trading volume exceeding 10 million shares, the company remains on the radar of multiple large pharmaceutical acquirers.